The $200 Billion Supply Test: Can Markets Absorb the 2026 IPO Wave?

The 2026 IPO market is running at a pace that would have seemed implausible eighteen months ago. U.S. IPO proceeds have reached $114.7 billion across 82 priced deals year-to-date{{cite:chatcmpltool}}, and global equity capital markets issuance hit $729.4 billion in the first half — the highest H1 volume since 2021{{cite:chatcmpltool}}. The central question is no longer whether the window is open. It is whether the market can absorb what is coming through it without forcing investors to liquidate the holdings that drove the rally in the first place.

The numbers behind the surge

The headline figure conceals an important compositional shift. Deal count is actually down 18% year-over-year{{cite:chatcmpltool}}, but average deal size has exploded. The reason is a single transaction: SpaceX’s June 12 IPO, which raised $75 billion at $135 per share — 555.6 million shares — making it the largest public debut in history{{cite:chatcmpltool}}. With the full exercise of the underwriters’ over-allotment option, the total reached approximately $86 billion{{cite:chatcmpltool}}. At pricing, SpaceX carried a $1.77 trillion valuation; on its first trading day the stock closed near $161, a roughly 20% pop that pushed the market capitalization above $2.1 trillion and left Alphabet’s stake worth close to $100 billion{{cite:chatcmpltool}}.

Beyond SpaceX, the pipeline is broadening. Lime (Neutron Holdings) priced its IPO at $25 — the midpoint of a $24–$26 range — raising $174 million at a $1.6 billion market cap, with existing shareholder Uber indicating on $20 million of the deal{{cite:chatcmpltool}}. The stock opened at $27 on its Nasdaq debut, an 8% first-day gain{{cite:chatcmpltool}}. It is a modest deal by 2026 standards, but it signals that the window is open beyond mega-cap AI.

Globally, LSEG reports total equity issuance up 72% in the first six months of 2026 to $568.8 billion, with deal volume up 10%{{cite:chatcmpltool}}. Federal Reserve data shows $389 billion in new U.S. stock issuance in Q1 alone — the second-largest quarterly total in records dating to 1996{{cite:chatcmpltool}}.

The supply-absorption debate

The worry is straightforward: if $200 billion or more of new equity enters the market, investors must raise cash to buy it, and that means selling something else. One widely circulated analysis projects that a $200 billion IPO wave could displace as much as $1 trillion in existing stock market value{{cite:chatcmpltool}}.

UBS pushes back. In a June 22 note, the firm’s CIO argues that record issuance “shouldn’t be a headwind” because corporate buybacks more than offset the net supply{{cite:chatcmpltool}}. UBS forecasts full-year IPO issuance of $200–350 billion, with secondary offerings surging alongside{{cite:chatcmpltool}}. The logic: gross issuance rises, but buybacks and dividend reinvestment keep net capital flows positive — money comes in faster than it goes out.

The counter-argument is that this cycle is different in composition. The two largest H1 deals — SpaceX’s $75 billion IPO and Alphabet’s $85 billion equity raise to fund its AI buildout{{cite:chatcmpltool}} — are both capital-hungry infrastructure bets, not mature companies returning cash. When the issuers themselves are net capital consumers, the buyback-offset thesis weakens. J.P. Morgan frames the tension directly: the IPO wave is historic, and so is the market that must absorb it{{cite:chatcmpltool}}.

Put numbers on it: I’d estimate the probability that gross issuance meaningfully dampens broad index returns over the next two quarters at roughly 35%. The 65% base case is that buybacks, passive inflows, and money-market rotation absorb the supply — but that assumes no volatility shock that forces underwriters to pause the calendar, as happened in Q1 when 35 IPOs raised capital amid a tech sell-off, tariff turmoil, and Middle East conflict{{cite:chatcmpltool}}.

The H2 pipeline: Anthropic, Lambda, and the OpenAI question

The second-half pipeline is where the supply test intensifies. Anthropic has confidentially filed S-1 paperwork for an IPO, potentially reaching the public market this fall{{cite:chatcmpltool}}. The filing follows a $65 billion funding round at a $965 billion valuation, with projected Q2 revenue of $10.9 billion and Anthropic on pace for its first profitable quarter{{cite:chatcmpltool}}. Lambda, an AI infrastructure company, is reportedly planning an H2 2026 listing{{cite:chatcmpltool}}.

The wildcard is OpenAI. PitchBook reports that OpenAI may delay its IPO to 2027 — a scenario that would remove the single most anticipated listing from the 2026 calendar{{cite:chatcmpltool}}. If OpenAI slips, it would reduce headline supply but also remove a potential catalyst that has been pulling institutional capital toward the new-issue market. Renaissance Capital’s assessment is blunt: “Every 2026 IPO is AI infrastructure”{{cite:chatcmpltool}}.

Market structure: the SEC’s NMS proposal

While issuance dominates the headlines, a quieter market-structure shift could reshape how U.S. equities trade. On June 11, 2026, the SEC proposed rescinding Rule 611 of Regulation NMS — the Order Protection Rule, also known as the trade-through rule — along with Rule 610(e), the prohibition on locked and crossed markets{{cite:chatcmpltool}}. Rule 611 has required exchanges to route orders to the venue displaying the best price for two decades; removing it would allow trading at inferior prices if the executing venue offers other benefits, such as speed or liquidity.

Skadden, Sidley Austin, and other legal analysts call it one of the most significant equity market-structure proposals in a generation{{cite:chatcmpltool}}. The implications extend beyond traditional exchanges: Galaxy and other crypto analysts argue that rescinding the trade-through rule removes a legal barrier to tokenized U.S. stocks trading on decentralized platforms, since DeFi venues cannot guarantee NMS-compliant price routing{{cite:chatcmpltool}}.

Separately, the CFTC and SEC jointly issued a request for comment on June 18 to clarify the boundary between “swaps” and “security-based swaps” and to harmonize portfolio margining rules across the two agencies{{cite:chatcmpltool}}. The comment period is open; adoption timelines remain uncertain, but the direction of travel is toward deregulation and cross-agency harmonization.

The leveraged-ETF warning from Seoul

A market-structure risk worth flagging is emerging in South Korea, where the Bank of Korea on July 5 joined a chorus of regulators warning that single-stock leveraged ETFs tied to Samsung Electronics and SK Hynix are amplifying concentration risk and market volatility{{cite:chatcmpltool}}. Roughly $9 billion has piled into semiconductor-linked leveraged ETFs, and total domestic leveraged-ETF assets under management surged 431% over the past year to 36.52 trillion won{{cite:chatcmpltool}}.

The BOK flagged a “wag the dog” dynamic in which derivative flows — one-way retail buying amplified by daily leverage resets — are moving the underlying stocks rather than reflecting fundamental demand{{cite:chatcmpltool}}. Overseas platforms are now offering products with up to 150x leverage on Kospi indices, prompting regulators to consider raising investment entry barriers{{cite:chatcmpltool}}.

This is not a U.S. story yet, but the pattern — retail-driven leveraged products concentrating in a few semiconductor names — rhymes with risks visible in U.S. single-stock leveraged ETFs tied to NVDA and other AI-exposed names. The Korean case is a real-time stress test of what happens when the derivatives tail grows large enough to wag the underlying.

What to watch next

1. Anthropic’s S-1 going public. The confidential filing moves to a public registration statement as the fall listing window approaches. The disclosed financials — revenue trajectory, margin profile, and the path to profitability — will set the valuation anchor for the entire AI-software IPO cohort.

2. OpenAI’s timing decision. If OpenAI confirms a 2026 listing, total H2 supply could push toward the upper end of UBS’s $350 billion estimate. A delay to 2027 removes the anchor deal but may free capital for other listings.

3. SEC NMS comment period and adoption timeline. Watch for the volume and tenor of public comments on the Rule 611 rescission proposal. Exchange operators, market makers, and crypto-tokenization advocates will weigh in with sharply different views on price protection versus execution flexibility.

4. Buyback cadence versus issuance. UBS’s bullish thesis depends on buybacks continuing to offset net supply. Q2 and Q3 buyback announcements from mega-cap tech will test whether the offset holds as issuance accelerates.

5. Korean regulatory response. If the BOK or Financial Services Commission raises leverage-ETF entry barriers or imposes position limits, watch for whether U.S. regulators take a parallel look at single-stock leveraged products concentrated in AI names.

6. Any volatility pause. The Q1 experience — where volatility grounded the IPO calendar after a strong start — is the template for what could interrupt H2. A single-week VIX spike above 25 would likely cause underwriters to pull deals, temporarily tightening the supply pipeline.

7. Lambda’s filing. As a pure-play AI infrastructure company targeting H2, Lambda’s S-1 will provide a direct read on how the market values GPU compute capacity and data-center buildout outside the mega-cap umbrella.